18,500
Participants
Start Date
November 25, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
March 31, 2026
Arpraziquantel 150mg dispersible tablet
Arpraziquantel 150mg dispersible tablets given as single oral dose of 50mg/kg (in Kenya and Uganda; for Schistosoma mansoni infection) or 60mg/kg (in Côte d'Ivoire; for mixed infections with S. mansoni / S. haematobium) using weight-based dosing tables as detailed in the summary of product characteristics.
RECRUITING
Programme National de Lutte Contre les Maladies Tropicales Négligées à Chimiothérapie Préventive (PNLMTN-CP), Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle (MSHPCMU), Abidjan
RECRUITING
Université Félix Hophouët-Boigny (UFHB), Département de sociologie, Abidjan
RECRUITING
Université Félix Hophouët-Boigny (UFHB), UFR Biosciences, Abidjan
NOT_YET_RECRUITING
African Institute for Health and Development (AIHD), Nairobi
NOT_YET_RECRUITING
Kenya Medical Research Institute (KEMRI), Eastern and Southern Africa Centre of International Parasite Control (ESACIPAC), Nairobi
NOT_YET_RECRUITING
Makerere University, Department of Sociology and Anthropology, Kampala
NOT_YET_RECRUITING
Vector Borne & Neglected Tropical Disease Control Division, Ministry of Health, Kampala
Collaborators (1)
Technical University Munchen
UNKNOWN
Makerere University
OTHER
African Institute for Health and Development, Kenya
UNKNOWN
Kenya Medical Research Institute
OTHER
Kenya Ministry of Health
OTHER_GOV
Ministry of Health, Uganda
OTHER_GOV
Ministère de la Santé, de l'Hygiène Publique et de la Couverture Maladie Universelle
UNKNOWN
Université Félix Hophouët-Boigny
UNKNOWN
Unlimit Health
UNKNOWN
Peter Steinmann
OTHER